Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?

Cellectar Biosciences Inc CLRB announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that have received at least two prior lines of therapy. Waldenström…#wam #waldenstrom #waldenström #iopofosinei131
Source: Reuters: Health - Category: Consumer Health News Source Type: news